Ipsen Sa · EURONEXT:IPN
Ipsen Sa — Investor Day (December 2023)
88 slides from Ipsen Sa's investor day presentation, Dec 7, 2023
Slide 1: Capital Markets Day
Capital Markets Day 7 December 2023
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Agenda
Agenda David Loew Aymeric Le Chatelier Christelle Huguet CEO CFO Head of R&D Strategic outlook Strong financial R&D & sustainability pipeline review Q&A 1.30pm GMT Break 2.00-2.15pm GMT Bartek Bednarz Stewart Campbell Mari Scheiffele Head of Global Product President, President, International & Portf
Slide 4: Strategic outlook
Strategic outlook David Loew Chief Executive Officer
Slide 5: Our vision
Our vision To be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines Oncology Rare Disease Neuroscience
Slide 6: Our Executive Team
Our Executive Team Supporting Ipsen’s transformation David Loew Chief Executive Officer Catherine Abi-Habib Christelle Huguet Aidan Murphy Head of Strategy, Head of R&D Head of Technical Transformation & Digital Operations Bartek Bednarz Aymeric Le Chatelier Mari Scheiffele Head of Global Product Ch
Slide 7: Focus. Together. For patients
Our strategy Bringing full potential of our Building innovative medicines a high-value, to patients sustainable pipeline Focus. Together. For patients Delivering & society efficiencies to enable Boosting investments & a culture of support growth collaboration, excellence & impact on society 7
Slide 8: Focus. Together. For patients & society
Focus. Together. For patients & society Achievements since 2020 Bringing full potential of Building a high-value, Delivering efficiencies to Boosting a culture of our innovative medicines sustainable pipeline enable investments & collaboration, excellence to patients support growth & impact on socie
Slide 9: Our growth journey
Our growth journey Next phase of transformation built on solid foundations 2028+ Lasting momentum 2024-2027 Balanced & diversified Dynamic growth portfolio across three therapy areas 2020-2023 Several launches Sustained growth, Setting foundations supported by pipeline & Further pipeline expansion e
Slide 10: Bringing full potential of our innovative medicines to patients
Emperor to change picture – see attached in the email Bringing full potential of our innovative medicines to patients Steve Living with kidney cancer Crewe, U.K. 10
Slide 11: A strong platform for growth
A strong platform for growth Growth platforms & new medicines continue to drive momentum External innovation elafibranor New Total sales medicines Growth platforms Somatuline Today Time 11
Slide 12: Increasingly diversified portfolio
Increasingly diversified portfolio Seven medicines: potential sales ≥€500m 2027+ elafibranor Four medicines: sales ≥€500m 2023 One medicine: sales ≥€500m 2020 2023 sales based on latest available consensus forecasts. 12
Slide 13: Launching four new medicines or new indications in near term
Launching four new medicines or new indications in near term Building Rare Disease franchise & strengthening Oncology Medicine Indication Market Expected regulatory-decision date 1L mPDAC U.S. only FDA: Q1 2024 ALGS Global1 U.S. launch underway EMA: 2024 elafibranor 2L PBC Global2 FDA & EMA: H2 2024
Slide 14: More balanced split of sales by three therapy areas
More balanced split of sales by three therapy areas Oncology Rare Disease Neuroscience 76% 3% 21% of total of total of total sales1 sales1 sales1 Growth driven by Multiple launches: Sustained growth Onivyde 1L mPDAC & Bylvay, elafibranor & of Dysport in Tx & Ax Cabometyx Sohonos Future growth: Futur
Slide 15: Global leader with growth across all regions
Global leader with growth across all regions North America Europe Rest of World 33% 40% 27% of total sales1 of total sales1 of total sales1 Leveraging platform through Sustained growth driven by Multiple opportunities in multiple launches Dysport & Cabometyx Asia-Pacific & Latin America Future growt
Slide 16: Strong U.S. growth driven by multiple potential launches
Strong U.S. growth driven by multiple potential launches U.S. sales Significant opportunities Growing footprint in Oncology – Onivyde 1L mPDAC – Tazverik Becoming established in Rare Disease – Building franchise in rare liver: elafibranor in 2L PBC, Bylvay in PFIC & ALGS – Launching first treatment
Slide 17: Building a high-value, sustainable pipeline
Building a high-value, sustainable pipeline 17
Slide 18: Fuelling high-value, sustainable pipeline
Fuelling high-value, sustainable pipeline Phase I Phase II Phase III Registration IPN60210 TAZVERIK CABOMETYX + ONIVYDE + 5-FU/LV + R/R multiple myeloma (+ hormonotherapy) ATEZOLIZUMAB OXALIPLATIN & R/R DLBCL mCRPC 2L mCRPC 1L mPDAC IPN60260 FIDRISERTIB TAZVERIK + R2 ODEVIXIBAT1 Viral cholestatic di
Slide 19: Continued pipeline execution
Continued pipeline execution Achieve up to three Complete up to five potential regulatory pivotal trials by 2026 approvals by 2024 Advance Expansion of LANT trials early-stage programs LANT: longer-acting neurotoxin. 19
Slide 20: Clear strategy to continue external innovation
Clear strategy to continue external innovation Oncology Rare Disease Neuroscience €300-800m peak sales Solid tumors & High unmet needs Rare neurological hematology in underserved rare disorders diseases Balance early – niche tumors & late-stage – biomarker segments assets Preference Smaller patient
Slide 21: Delivering efficiencies to enable investments & growth
Delivering efficiencies to enable investments & growth 21
Slide 22: Efficiencies to fuel growth
Efficiencies to fuel growth Strong budget Bring medicines to Leverage power of digital, discipline patients faster data & analytics Target investments to Accelerate submission Support R&D & go-to-market support launches & pipeline process execution Generate efficiencies from Deliver faster & expande
Slide 23: Boosting a culture of collaboration, excellence & impact on society
Boosting a culture of collaboration, excellence & impact on society 23
Slide 24: Driving a culture of impact throughout organization
Driving a culture of impact throughout organization People-centric Making culture a leadership strategic enabler Leveraging a very high level of engagement Global HQs designed to foster collaboration ` to create true impact Diversity as an enabler for great decisions Delivering competitive employee
Slide 25: Generation Ipsen: for positive change
Generation Ipsen: for positive change Environment Patients People Governance Caring for the At the heart of Making a real Acting with integrity planet everything we do impact, every day & transparency 50% reduction in Reducing time 50% women in Senior-leadership absolute Scope 1 & 2 from FDA/EMA to
Slide 26: Our mid-term priorities
Our mid-term priorities Continue pipeline delivery, supported by external innovation Maximize value of medicines with four successful launches Deliver on sustainability roadmap
Slide 27: Strong financial sustainability
Strong financial sustainability Aymeric Le Chatelier Chief Financial Officer
Slide 28: Solid 2023 financials
Solid 2023 financials Total sales1 Core operating Firepower2 margin1 for external innovation >6.0% >30% ~€1.7bn at constant of total sales at end of June 2023 exchange rates – Growth platforms: – R&D & SG&A investment – Based on net debt1 at double-digit growth from recent acquisitions 2.0x EBITDA –
Slide 29: On track to deliver 2020 Capital Markets Day targets
On track to deliver 2020 Capital Markets Day targets Outlook 2020-2024 Performance to date CMD December 2020 CMD December 2023 Total-sales CAGR 2020-24 Total-sales CAGR 2020-23 >8%2 between +2% & +5%1 Commitment to invest in R&D, SG&A expenses ratio: -4 %pts to 36% in 20233 supported by SG&A efficie
Slide 30: 2027 mid-term outlook
2027 mid-term outlook Excluding potential additional late-stage1 external-innovation opportunities TOTAL-SALES: CORE OPERATING CAGR 2023-2027 MARGIN 2027 ≥+7% ≥32% of total sales at constant exchange rates ` Launches of new medicines & Limited decline in additional indications gross-margin Growth pl
Slide 31: Multiple growth opportunities by medicine
Multiple growth opportunities by medicine Global peak sales / direction Peak sales >€700m1 Peak sales >€500m2 Oncology Peak sales >€500m3 Mid-single digit growth4 Peak sales >€700m5 Rare Disease Elafibranor Peak sales >€500m6 Peak sales >€100m Neuroscience High-single digit growth4 1 Excluding addit
Slide 32: Drivers of 2027 core operating margin
Drivers of 2027 core operating margin Gross margin R&D SG&A ≥85% ≥20% ≤35% Manufacturing gains Investment to support Leverage commercial to lower unit costs internal & external infrastructure & targeted innovation pipeline investment for launches Unfavorable sales mix Optimization of footprint Syner
Slide 33: Capital-allocation framework
Capital-allocation framework Cumulative firepower of up Increased free Limited to €5bn by 2027, based on net cash-flow evolution debt1 at 2.0x EBITDA generation of dividend Priority for capital allocation Multiple transactions from licensing & acquisitions External Innovation Financial discipline ba
Slide 34: Long-term growth & value creation
Long-term growth & value creation Sales growth Strong sales growth External Innovation Operating leverage & solid cash-flow conversion Operating leverage Investment for external innovation Cash generation Long-term delivery to drive Margin significant value creation for Financial improvement shareho
Slide 35: R&D and pipeline review
R&D and pipeline review Christelle Huguet Head of R&D
Slide 36: A compelling & focused R&D platform
A compelling & focused R&D platform Uniting expertise to bring new treatment options to patients around world Accelerating innovation & excellence in execution Truly global-trial designs, based on patient insights >700 4 End-to-end: molecule to patient colleagues R&D hubs dedicated to R&D across U.S
Slide 37: Accelerating innovation through partnerships
Accelerating innovation through partnerships Striving for best- or first-in-class programs Right science Right potential What the partner brings What Ipsen brings Evaluation & identification of scientific potential Excellence in global clinical & regulatory execution Early Strong target Clinical dis
Slide 38: Bringing new acquisitions, licenses & partnerships into our portfolio
Bringing new acquisitions, licenses & partnerships into our portfolio Great partnerships create great possibilities Preclinical Clinical Marketed 38
Slide 39: Delivering our R&D strategy
Delivering our R&D strategy Strong expansion with >20 new programs1 Executing on pipeline Integration with continued program execution Continued delivery of portfolio milestones of two acquisitions in nine months Strengthened expertise & focus in Advancing early development programs Rare Disease Exp
Slide 40: Fuelling a high-value, sustainable pipeline
Fuelling a high-value, sustainable pipeline Early development Phase I Phase II Phase III Registration IPN01194 IPN60210 TAZVERIK CABOMETYX + ONIVYDE + 5-FU/LV + R/R multiple myeloma (+ hormonotherapy) ATEZOLIZUMAB OXALIPLATIN & R/R DLBCL mCRPC 2L mCRPC 1L mPDAC IPN01195 IPN60260 FIDRISERTIB TAZVERIK
Slide 41: Onivyde: topoisomerase inhibitor investigated in 1L mPDAC
Onivyde: topoisomerase inhibitor investigated in 1L mPDAC NAPOLI-3: Phase III open-label, randomized global, multi-center trial (n=770) First positive Phase III trial in >10 years, NAPOLI-3 published in The Lancet, September 20231 100 90 Arm Median (95% CI) Hazard ratio (95% CI) p value NALIRIFOX 11
Slide 42: Cabometyx: TKI investigated in mCRPC
Cabometyx: TKI investigated in mCRPC – patients previously treated with NHT CONTACT-02: Phase III open-label, randomized, global, multi-center trial (n=575) Primary endpoints Safety profile Trial ongoing: of PFS & OS consistent anticipate additional – PFS met with known profiles OS data of each medi
Slide 43: Tazverik: selective EZH2 inhibitor investigated in R/R FL patients
Tazverik: selective EZH2 inhibitor investigated in R/R FL patients Accelerated Approval in June 2020 in U.S. SYMPHONY-1: Phase Ib/III global, double-blind, randomized, active-controlled trial (n=540) Phase Ib 18-months data-cut median PFS – 79.5%1 ASH 2023: 22.5-month median follow-up oral-poster pr
Slide 44: Bylvay (odevixibat): potent, non-systemic iBAT inhibitor
Bylvay (odevixibat): potent, non-systemic iBAT inhibitor Potential in three rare liver indications PFIC indication approved PEDFIC 1 +2: Phase III, placebo-controlled, global, multi-center trial in U.S. & E.U. in 2021 (n=62) + OLE Alagille syndrome ASSERT: Phase III double-blind, randomized, placebo
Slide 45: Bylvay (odevixibat): evaluation in biliary atresia
Bylvay (odevixibat): evaluation in biliary atresia BOLD: Phase III double-blind, randomized, placebo-controlled, global, multi-center trial (n=245) Phase III clinical-endpoint trial ongoing 24-month treatment: – primary endpoint: time from 1:1 randomization randomization to first event (liver transp
Slide 46: Elafibranor: dual PPAR-α/δ agonist investigated in PBC
Elafibranor: oral, dual PPAR-α/δ agonist investigated in patients with PBC with inadequate response or intolerance to UDCA ELATIVE: Phase III double-blind, randomized, placebo-controlled trial (n=162) Data presented at AASLD, 2023 - simultaneous ELATIVE biochemical response at Week 521 publication i
Slide 47: Elafibranor: ELATIVE secondary endpoints
Elafibranor: ELATIVE secondary endpoints ELATIVE: Phase III double-blind, randomized, placebo-controlled trial (n=161) Only patients treated with Elafibranor may improve elafibranor achieved ALP moderate-to-severe pruritus normalization in patients with PBC – Baseline mean – Trend for improvement in
Slide 48: Building on Ipsen's expertise in rare liver disease
Building on Ipsen’s expertise in rare liver disease PSC: rare progressive liver disorder characterised by inflammation of the bile ducts, leading to cholestasis, fibrosis & liver failure1 Phase IIb double-blind, randomized, placebo-controlled, multi-center trial with open-label extension evaluating
Slide 49: Fidrisertib: selective inhibitor of mutated ALK2-receptor in FOP
Fidrisertib: highly potent, selective inhibitor of kinase domain of mutated form of ALK2-receptor in FOP FALKON: randomized, placebo-controlled, global, multi-center, pivotal trial (n=98) Differentiated mechanism to Sohonos BMPs, Activins, … Enrolling FOP patients from ALK2R206H BMP Type II five yea
Slide 50: LANT: therapeutic & aesthetic evaluation
LANT: therapeutic & aesthetic evaluation LANTIMA (n=209) & LANTIC (n=191): Phase II ongoing global, double-blind, multi-center trials Evaluating safety & efficacy – LANTIMA: adult upper-limb spasticity – LANTIC: severe upper-facial lines Dose escalation & dose-finding trial Recombinant toxin, engine
Slide 51: Near to mid-term outlook
Near to mid-term outlook Data Regulatory readout decision Key milestones Medicine 2024 2025 2026 Onivyde 1L mPDAC, FDA Elafibranor 2L PBC, FDA Odevixibat ALGS, E.U. Cabometyx mCRPC, Phase III Fidrisertib FOP, Phase II Bylvay BA, Phase III Dysport Migraine, Phase III Tazverik 2L FL, Phase III1 1L: fi
Slide 52: Focus on continued expansion & excellence in execution
Focus on continued expansion & excellence in execution External Executing on innovation pipeline Building a diverse & Focusing on high-value sustainable pipeline programs delivering across three better outcomes for therapy areas patients
Slide 53: Questions
Capital Markets Day Questions 7 December 2023 John Living with prostate cancer Lincolnshire, U.K.
Slide 54: Capital Markets Day
Capital Markets Day 7 December 2023
Slide 55: Portfolio review: Dysport, Somatuline, Decapeptyl & Cabometyx
Portfolio review Dysport, Somatuline, Decapeptyl & Cabometyx Bartek Bednarz Head of Global Product & Portfolio Strategy
Slide 56: Growing across Oncology, Rare Disease & Neuroscience
Growing across Oncology, Rare Disease & Neuroscience Commercial Strong commercial, priorities medical & access capabilities Driving launches Global platform Capturing full potential First or second position of growth platforms in disease areas where we operate Optimizing value of Somatuline
Slide 57: Addressing multiple indications across three therapy areas
Addressing multiple indications across three therapy areas Oncology Rare Disease Neuroscience Pancreatic PFIC Spasticity cancer Renal cell Alagille Liver Cervical dystonia carcinoma syndrome Solid tumors Hepatocellular Primary biliary Aesthetic elafibranor carcinoma cholangitis indications Prostate
Slide 58: Dysport: attractive growth
Dysport: attractive growth Dysport sales Outlook & drivers (€m) Attractive market growth in Tx & Ax, 594 returning to pre-pandemic levels 388 435 348 353 New competitors but significant barriers to entry 2018 2019 2020 2021 2022 Investment in manufacturing capacity at Wrexham to meet market-growth p
Slide 59: Dysport: large & growing market in Ax
Dysport: large & growing market in Ax Ax global botulinum toxin Market dynamics market (2022) Asia- Pacific North Significant ‘Zoom boom’ through the pandemic America 22% Increased patient awareness & acceptance driven by social media ~€4bn 58% 14% New customer segments 5% Ease of access & availabil
Slide 60: Dysport: strong franchise in Ax
Dysport: strong franchise in Ax Global player, with partnership covering territories in >75% of global Ax market Leadership position: #1 or #2 Strong performance across all geographies, including market-share gains Recent & new entrants Well positioned for continued growth in Ax Ax: aesthetics 60
Slide 61: Dysport: attractive market in Tx
Dysport: attractive market in Tx Tx global botulinum-toxin Market dynamics market (2022) ~€3bn Significant unmet need in post-stroke spasticity – U.S. incidence: ~640k patients Ongoing 37% Migraine – Treated with BoNT-A (U.S.): ~15% Ph. III Some indications 19% Other Improved diagnosis & treatment o
Slide 62: Somatuline: sales erosion as planned
Somatuline: sales erosion as planned Year-on-year sales growth Outlook & drivers More lanreotide & somatostatin entrants Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 expected over time in U.S. & E.U. & selected countries Reduced sales/marketing activity Growth in some RoW markets with no generics / ret
Slide 63: Decapeptyl: continued growth story
Decapeptyl: continued growth story Decapeptyl sales Outlook & drivers (€m) Attractive market dynamics – ADTs remain backbone therapy in prostate 530 460 cancer2 373 407 391 – Epidemiology driven by aging population Potential for 3M & 6M formulations in additional markets 2018 2019 2020 2021 2022 Con
Slide 64: Cabometyx: strongly positioned as TKI of choice in RCC
Cabometyx: strongly positioned as TKI of choice in RCC Cabometyx sales Outlook & drivers (€m) Strong market share gain potential 1L RCC in 449 combination with nivolumab in countries where 355 reimbursed 289 242 148 Consolidation of market leadership in 2L RCC once patients progress from 1L combinat
Slide 65: Cabometyx: headroom to grow in 1L RCC
Cabometyx: headroom to grow in 1L RCC 1L RCC – Cabometyx in combination with 1L RCC total patient share: E5 nivolumab: total patient share Italy, France, Germany Number of eligible patients: ~20k (E5) Total patient New patient Q3 ‘23 share share Combination median PFS: 16.6 months Italy 21% 29% Fran
Slide 66: Cabometyx: consolidating market leadership in 2L RCC
Cabometyx: consolidating market leadership in 2L RCC 2L RCC – Cabometyx monotherapy 2L RCC total patient share – E5 Total patient share – E5 Number of eligible patients: ~10k (E5) 45 Median PFS: 7-10 months 34% 35 100% 100% 25 23% CPI 44% 59% 15 (CPI or CPI+TKI) Q1’20 Q3’23 Strong HCP confidence, tr
Slide 67: Portfolio review: Onivyde, Tazverik & Sohonos
Portfolio review Onivyde, Tazverik & Sohonos Stewart Campbell President, North America
Slide 68: Onivyde: growth to come from indication extension
Onivyde: growth to come from indication extension Onivyde sales1 Outlook & drivers (€m) Significant potential in 1L mPDAC, with high 162 unmet medical need & low one-year survival rate 135 123 127 109 Continued utilization in post-gem mPDAC Limited number of new competitors expected 2018 2019 2020 2
Slide 69: Onivyde: significant potential in 1L mPDAC
Onivyde: significant potential in 1L mPDAC U.S. Phase III NAPOLI-3 trial: annual incidence of patients receiving treatment positive results Patients not receiving Differentiated clinical profile any active treatment / & strong data deceased patients 1L ~35k patients1 PDUFA date: 13 February 2L 2024,
Slide 70: Onivyde: increasing share in 1L mPDAC
Onivyde: increasing share in 1L mPDAC U.S. 1L mPDAC market % of active patients1 Potential to become new SoC in 1L mPDAC by gaining market 100% share in all segments Onivyde 2% irinotecan-based 43% Building on our footprint in pancreatic cancer gem-based 41% Leveraging strong commercial Other² & med
Slide 71: Tazverik: initial platform in hematology, long-term potential
Tazverik: initial platform in hematology, long-term potential Tazverik U.S. sales1 Outlook & drivers (€m) 36 Mid term – Focus on U.S., with new field force in place 24 – Unique opportunity in community setting 11 – Expansion into wild-type patients – Improving access pathway, given favorable tolerab
Slide 72: Tazverik: larger potential in 2L combination
Tazverik: larger potential in 2L combination1 FL – U.S. number of treated patients Larger patient pool & longer DoT in 2L FL Patients not receiving any active treatment / deceased patients Potential to launch ex. U.S Highly combinable profile: 2L FL opportunity to expand 4.6k patients 3L+ FL usage i
Slide 73: Sohonos: first & only treatment approved in FOP
Sohonos: first & only treatment approved in FOP “A treatment option for FOP is so important for [my son] Hayden and the FOP community. A treatment truly gives hope to this community.” Megan Olson, FOP Caregiver and IFOPA Board Chair “Today is a monumental day for the FOP community!...We express our
Slide 74: Sohonos: regulatory approval in U.S. in 2023
Sohonos: regulatory approval in U.S. in 2023 >400 prevalent patients in U.S. Indication – >250 identified Reduction in volume of HO in adults – Of which, ~30% are ineligible & pediatric patients with FOP aged ▪ Below eight and 10 years old >eight years for females & ▪ Above 20-25 years old, joints >
Slide 75: Portfolio review: Bylvay & elafibranor
Portfolio review Bylvay & elafibranor Mari Scheiffele President, International
Slide 76: Bylvay: expanding position in rare liver disease
Bylvay: expanding position in rare liver disease Bylvay sales (€m)1 Outlook & drivers 23 Strong uptake in PFIC & ALGS 18 – Increasing number of new patients 15 9 7 – Weight-based dose increases 11 6 7 – Ease of administration, fosters patients’ 4 3 11 13 convenience 9 4 6 – Geographic expansion Q3’2
Slide 77: Bylvay: U.S. growth based on two approved indications
Bylvay: U.S. growth based on two approved indications Bylvay – reimbursed U.S. PFIC patients U.S. outlook & drivers PFIC 150 143 – Addressing pediatric & adult patients 125 – Drive growth from iBAT-naïve physicians 106 – Expanding into secondary hepatology 100 centers to accelerate patient finding 8
Slide 78: Bylvay: growth enhanced by geographic expansion
Bylvay: growth enhanced by geographic expansion Bylvay launch sequence: Ex. U.S. outlook & drivers national reimbursement 2021 2022 2023 Further patient uptake from existing markets PFIC U.S. France Netherlands Multiple additional countries with regulatory approval & pricing/reimbursement in Germany
Slide 79: Elafibranor: PBC, a rare autoimmune liver disease
Elafibranor: PBC, a rare autoimmune liver disease U.S. E5 RoW ~100k ~95k ~190k Patients diagnosed with PBC Patients diagnosed with PBC Patients diagnosed with PBC ~75k ~75k ~140k Patients treated in 1L Patients treated in 1L Patients treated in 1L PBC: primary biliary cholangitis; 1L: first line; E5
Slide 80: Elafibranor: opportunity to expand global 2L PBC market
Elafibranor: opportunity to expand global 2L PBC market U.S. example: 2L PBC patient flow: Underdeveloped global 2L PBC market number of U.S. patients Significant unmet medical need – Dissatisfaction with current treatment options – Uncontrolled disease Limited share (20-40%) of eligible patients Pa
Slide 81: Elafibranor: U.S. launch readiness on track
Elafibranor: U.S. launch readiness on track Patient profile & landscape U.S. launch readiness 80% of patients are women Established U.S. Rare Disease organization preparing Mean age of first diagnosis is 50 years old for rapid launch 70% of patients have at least one – Educating HCPs & patients on n
Slide 82: Conclusion
Conclusion David Loew Chief Executive Officer
Slide 83: Conclusion
Conclusion Successfully executing on a consistent strategy to continue our growth journey Advancing the Excellence in 2027 pipeline execution mid-term outlook1 Focused platform across Commercial & medical Total-sales growth: three therapy areas execution underpinning CAGR, 2023-2027 attractive oppor
Slide 84: Q&A
David Loew Bartek Bednarz Q&A CEO Head of Global Product & Portfolio Strategy Aymeric Le Chatelier Stewart Campbell CFO President, North America Christelle Huguet Mari Scheiffele Head of R&D President, International
Slide 85: Questions
Capital Markets Day Questions 7 December 2023 Diana Living with post-stroke spasticity Sintra, Portugal
Slide 86: Investor Relations
Investor Relations Craig Marks Nicolas Bogler Vice President, Investor Relations Investor Relations Senior Manager +44 7564 349 193 +33 6 52 19 98 92 craig.marks@ipsen.com nicolas.bogler@ipsen.com 86
Slide 87: Your feedback
Your feedback To optimize future Ipsen events, we would appreciate your feedback on the 2023 Capital Markets Day Thank you 87
Slide 88: Thank you
Thank you Follow us: www.ipsen.com